Set to launch this month, a recently approved blood test to detect biomarkers for Alzheimer’s disease could bring diagnosis into everyday clinical practice. In turn, this may support earlier intervention approaches that may help patients, their families and caregivers. The diagnostic, called a Lumipulse G Plasma Ratio test, is the first of its kind to get marketing clearance from the Food and Drug Administration. Until now, diagnosing Alzheimer’s has often relied on costly and invasive tools like a PET scan or lumbar puncture. The blood test could reduce the need for intrusive diagnostics. Recently approved disease-modifying therapeutics that can modestly reduce the rate of cognitive decline may amplify the importance of having a convenient test.

Alzheimer’s disease affects approximatel

See Full Page